MacroGenics, Inc. (NASDAQ:MGNX) Shares Acquired by Vestal Point Capital LP

Vestal Point Capital LP increased its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 3.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 830,000 shares of the biopharmaceutical company’s stock after purchasing an additional 30,000 shares during the quarter. Vestal Point Capital LP owned 1.32% of MacroGenics worth $2,731,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. BNP Paribas Financial Markets grew its holdings in MacroGenics by 374.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 90,779 shares of the biopharmaceutical company’s stock worth $299,000 after acquiring an additional 71,643 shares in the last quarter. FMR LLC grew its stake in shares of MacroGenics by 1,230.1% during the third quarter. FMR LLC now owns 137,215 shares of the biopharmaceutical company’s stock worth $451,000 after purchasing an additional 126,899 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of MacroGenics during the third quarter worth $68,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in MacroGenics by 39.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 661,914 shares of the biopharmaceutical company’s stock valued at $2,178,000 after buying an additional 186,858 shares during the last quarter. Finally, GSA Capital Partners LLP raised its stake in MacroGenics by 117.2% in the third quarter. GSA Capital Partners LLP now owns 207,877 shares of the biopharmaceutical company’s stock valued at $684,000 after buying an additional 112,188 shares in the last quarter. Hedge funds and other institutional investors own 96.89% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on MGNX shares. JMP Securities downgraded MacroGenics from an “outperform” rating to a “market perform” rating in a report on Thursday, November 7th. BMO Capital Markets dropped their price target on shares of MacroGenics from $8.00 to $5.00 and set a “market perform” rating on the stock in a research note on Wednesday, August 7th. BTIG Research downgraded shares of MacroGenics from a “buy” rating to a “neutral” rating in a research report on Thursday, August 1st. HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 target price on shares of MacroGenics in a research report on Wednesday, November 6th. Finally, StockNews.com raised shares of MacroGenics from a “sell” rating to a “buy” rating in a research report on Sunday, November 10th. Eight analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, MacroGenics presently has a consensus rating of “Hold” and an average price target of $7.63.

MacroGenics Price Performance

NASDAQ MGNX opened at $3.64 on Friday. MacroGenics, Inc. has a 52-week low of $2.95 and a 52-week high of $21.88. The business’s 50-day moving average price is $3.65 and its 200 day moving average price is $3.98.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.